- Previous Close
27,150.00 - Open
27,125.00 - Bid 26,950.00 x --
- Ask 27,950.00 x --
- Day's Range
27,025.00 - 27,475.00 - 52 Week Range
14,700.00 - 29,800.00 - Volume
1,876 - Avg. Volume
249 - Market Cap (intraday)
116.423T - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
4.70 - EPS (TTM)
5,844.11 - Earnings Date Nov 19, 2024
- Forward Dividend & Yield 621.45 (2.26%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
--
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
www.medtronic.comRecent News: MDT.BA
View MorePerformance Overview: MDT.BA
Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDT.BA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDT.BA
View MoreValuation Measures
Market Cap
116.42T
Enterprise Value
136.12T
Trailing P/E
4.70
Forward P/E
2.56
PEG Ratio (5yr expected)
0.26
Price/Sales (ttm)
0.57
Price/Book (mrq)
0.37
Enterprise Value/Revenue
4.25
Enterprise Value/EBITDA
16.70
Financial Highlights
Profitability and Income Statement
Profit Margin
12.06%
Return on Assets (ttm)
4.41%
Return on Equity (ttm)
7.95%
Revenue (ttm)
32.58B
Net Income Avi to Common (ttm)
3.93B
Diluted EPS (ttm)
5,844.11
Balance Sheet and Cash Flow
Total Cash (mrq)
7.84B
Total Debt/Equity (mrq)
57.86%
Levered Free Cash Flow (ttm)
4.9B